Alpha-lipoic acid in the treatment of diabetic polyneuropathy

Close metadata

Recommended articles:

Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74

Endothelial dysfunction as a pathogenetic factor of sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2024;(1):21-27

Causes of hospital mortality in adults based on medical certificates of death. Russian Journal of Preventive Medicine. 2024;(3):7-13

Oxidative stress prevention as an effective preventive strategy in type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2024;(3):117-123

Optimizing the treatment of diabetic ketoacidosis. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):67-77

Modern issues of lung tuberculosis and diabetes mellitus on the tobacco consumption background in the world and the Russian Federation. Russian Journal of Preventive Medicine. 2024;(4):97-102

Outcomes of bimanual vitreoretinal surgery in the treatment of diabetic retinopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27

Impact of SGLT2 inhibitors on erythropoiesis and iron exchange in patients with diabetes mellitus and chronic heart failure. Russian Journal of Preventive Medicine. 2024;(5):103-110

Incidence of carbohydrate metabolism disorder in iron overload of different etiology. Russian Journal of Preventive Medicine. 2024;(5):111-117

Fatal case of rhinocerebral mucormycosis on the background of type II diabetes mellitus. Russian Journal of Archive of Pathology. 2024;(3):52-58

The issues of classification, pathogenesis, pathomorphology and treatment of diabetic polyneuropathy (DPN) are addressed. Pathogenetic mechanisms of the action of alpha-lipoic acid in treatment of DPN are justified. The authors present the results of randomized placebo-controlled trials of alpha-lipoic acid that revealed the high clinical efficacy and absence of side-effects even during the long-term treatment.

Keywords:

diabetes mellitus

diabetic neuropathies

oxidative stress

endothelial dysfunction

alpha-lipoic acid

Authors:

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova A.S.

List of references:

Levin OS. Polyneuropathy. M.: MIA; 2011. (In Russ.)
Borodulina VI, Rachyn AP. Polyneuropathy in clinical practice: features of pathogenesis, clinics and modern approaches to the treatment of painful and painless forms. RMJ. 2016;25:1705-1710. (In Russ.)
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(1):62-67.
Boulton A, Tesfaye S. Diabetic neuropathy. Oxford; 2009.
Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33:2285-2293.
Ziegler D, Keller J, Maier C, Pannek J. Diabetic Neuropathy. German Diabetes Association: Clinical Practice Guidelines. Exp Clin Endocrinol Diabetes. 2014;22:406-415.
Kramer H, Rolke R, Hecht M. Follow-up of advanced diabetic neuropathy. J Neurol. 2005;252(3):315-320.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(1):62-67.
Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North. 2004;88:947-999.
Said G, Baudoin D, Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol. 2008;255:1693-1702.
Trence DL. Peripheral neuropathy in diabetes: is it diabetic neuropathy? Clin Diabetes. 2002;20:103-104.
Tesfaye S, Stevens LK, Stephenson JMС, Stephenson JM, Fuller M, Plater E, Ionesku-Tirgoviste А, Kollichesto G, Pozza GD, Yord F. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377-1384.
Arivazhagan P, Juliet P, Panneerselvam C. Effect of DL alpha-lipoic acid on the status of lipid peroxidation and antioxidants in aged rats. Pharmacol Res. 2000;41(3):299-303.
Gurer H, Ozgunes H, Oztezcan S, Ercal Н. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic Biol Med. 1999;27(1-2):75-81.
Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;46(1):15-28. https://doi.org/10.1177/2040622314552071
Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997;29:315-331.
Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA. Lipoic acid improves nerve blood ow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995;18:1160-1167.
Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16:1040-1043.
Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA. The ALADIN Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized doubleblind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31(3):171-179.
Andreassen CS, Jakobsen J, Andersen H. Muscle Weakness — A Progressive Late Complication in Diabetic Distal Symmetric Polyneuropathy. Diabetes. 2006;55:806-812.
Ametov AS1, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D. The SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY Trial. Diabetes Care. 2003;26:770-776.
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine. 2004;21:114-121.
Barancevich ER, Posokhin OV. Approaches to the treatment of neurological manifestations of diabetes. Journal of neurology and the psychiatrist im. S.S. Korsakova. 2010;110(4):63-66. (In Russ.)
Strokov IA, Ahmetzhanova LT, Solokha OA. Efficiency of treatment of diabetic polyneuropathy tablet form of alpha-lipoic acid. Difficult patient. 2010;8(3):17-21. (In Russ.)
Anikeeva OYu, Smirnova EN. Diagnosis and treatment of the preclinical stage of diabetic polyneuropathy. Effective pharmacotherapy. Endocrinology. 2010;3:3-6. (In Russ.)
Matveeva II, Trusov VV, Kuzmin EL, Solovjev AL. The Frequency of distal neuropathy and experience with the use of alpha-lipoic acid in patients with newly diagnosed type 2 diabetes. Difficult patient. 2017;4(5):7-11. (In Russ.)
Spravochnik lekarstv (In Russ.) http://medi.ru/doc/144420.htm/

Close metadata